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Minimizing Infant Exposure to and 
Risks from Medications while 
Breastfeeding 
The advantages ofbreastfeeding to the mother and newborn are many. Lactating mothers frequently 
ask about the safety of taking medications and the risk to their newborn. It is well established that 
all drugs are excreted into breast milk. However, most medications appear in only small amounts 
within the breast milk. With the availability of numerous resources on drug use while breastfeeding, 
a medication can be identified as contraindicated or compatible with breastfeeding. By understand-
ing the anatomy of the breast, principles oflactation, and drug passage into breast milk, an approach 
to minimize the transfer of the medications in the breast milk to the newborn can be developed. The 
plan should usually support and encourage the mother to continue to breastfeed her infant. Key 
words: breastfeeding, breast milk, drugs, lactation, medications 
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NO MATTER whether the agent is an over-the-counter medication or one pre-
scribed by a health care provider, most medi-
cations are detected in breast milk. The 
presence of a medication in breast milk may 
be inferred as a potential hazard to the 
infant, although only 1% to 2% of total 
maternal intake is likely to be found. 1 There-
fore the primary consideration in maternal 
drug therapy is the risk to the nursing infant, 
rather than the mere presence of the medica-
tion in the breast milk. Based on the many 
advantages of breastfeeding, the benefit of 
this physiologic process in the majority of 
cases far exceeds the potential risk. Few 
medications are truly contraindicated for 
the breastfeeding mother. While maternal 
medication therapy may be viewed as a 
reason for stopping breastfeeding, it usually 
should not be. 
PHYSIOLOGY OF LACTATION 
Understanding breast anatomy and the 
physiology oflactation is essential to com-
 
 
 prehending the complex interaction occur-
ring with maternal medication use during 
breastfeeding. 
Breast anatomy 
The basic structure of the breast is the 
alveolus, or acinus, which is composed of 
secretory cells where the terminal ductules 
end. Each cluster of secretory cells of the 
alveolus is surrounded by a contractile unit 
of myoepithelial cells responsible for eject-
ing milk into the ductules (Fig 1). Each 
terminal ductule then merges into the larger, 
lactiferous, or mammary, duct. Lactiferous 
ducts widen into the ampullae or lactifer-
ous sinuses located behind the nipple and 
the areola. The lactiferous sinus opens at 
the nipple (Fig 2). It is the compression on 
the lactiferous sinuses by the newborn's 
suck that causes breast milk to be expressed. 
Except for a small segment at the nipple 
opening where squamous epithelium lines 
the duct, the entire duct system is lined by 
a two-cell layer. The inner epithelial cell 
layer along the luminal side is surrounded 
by a spindled, interrupted layer of myoepi-
Alveolus-----...... 
(secretory cell) 
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thelial cells. The two-cell layer is sur-
rounded by a layer of basal lamina and 
delimiting fibroblast. 2 
Initiation and maintenance of lactation 
During pregnancy, maternal prolactin, 
progesterone, and estrogen levels increase. 
Prolactin is the major hormone responsible 
for lactation initiation and causes an increase 
in the number of secretory cells and prolactin 
receptors. During pregnancy, high levels of 
progesterone inhibit prolactin action. After 
birth the delivery of the placenta triggers a 
prolactin surge while progesterone and estro-
gen levels fall. The prolactin activates the 
secretory cells of the alveolus to manufacture 
breast milk. This initial milk production oc-
curs whether a newborn breastfeeds or not. 
Afterward the nursing newborn's suckling 
stimulates the afferent nerves to release pro-
lactin which causes milk synthesis (Fig 3). 
Prolactin levels remain elevated as long as 
breastfeeding occurs. With each breastfeeding 
episode there is a prolactin burst. The prolac-
tin burst is vital in maintaining milk volume, 
rather than a constantly elevated prolactin 
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Fig 1. Schematic diagram of the myoepithelial cells around the ductule opening into alveolus. 
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Fig 2. Schematic diagram of the breast. 
level. At the same time, the posterior pitu-
itary gland releases oxytocin, which medi-
ates the contraction of myoepithelial cells 
around the alveolus, causing milk ejection 
into the larger terminal ductule (Fig 4). Milk 
is moved along to the lactiferous sinuses, 
becoming available to the newborn via the 
openings in the nipple. 
Breast milk composition 
At the time of delivery, colostrum is 
present within the maternal breast. Colos-
trum is high in proteins and low in sugar 
and fat. As a result, colostrum is easy for 
the newborn to digest. Within 2 to 3 days 
after delivery, the secretion of milk be-
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Fig 3. Release and effect of prolactin. 
gins. The changes in milk composition 
continue for 10 days, when "mature milk" 
is established. Mature milk is higher in 
proteins and fat, thus higher in caloric 
content. 
PASSAGE OF DRUGS INTO BREAST 
MILK 
A medication given to a lactating mother 
follows an intricate route to the infant. The 
Posterior pituitary gland releases oxytocin 
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Fig 4. Release and effect of oxytocin. 
drug may be partially inactivated in the 
mother's liver, excreted in her urine, or dis-
tributed and protein bound. As a result, the 
free serum concentration in the mother is 
frequently low. When the medication is ab-
sorbed by the infant, it continues to undergo 
metabolism, renal excretion, protein bind-
ing, and tissue distribution. In addition, the 
 amount and frequency of breastfeeding will 
affect the concentration of the drug. Thus 
there are many factors that influence the 
passage of drugs into breast milk. These fac-
tors include the drug itself, maternal factors, 
infant factors, and the blood-milk barrier. 
Drug factors 
The drug's characteristics determine the 
amount of it that will be transferred into the 
breast milk. These characteristics include the 
molecular weight of the drug, the proportion 
of the drug that is bound to plasma and milk 
proteins, the solubility of the drug in lipids 
and in water, the proportion of the drug that 
is ionized or nonionized, the pH of the drug, 
and the half-life of the drug. 
Molecular weight 
The mammary epithelium membrane acts 
as a semipermeable lipid barrier. Small 
pores permit drugs with a low molecular 
weight to pass through. The lower the mo-
lecular weight of the drug, the easier the 
drug passes through to the milk. Drugs with 
a molecular weight of more than 200 
kilodaltons, such as heparin and insulin, 
are unable to cross the alveolar membrane. 3 
Protein binding 
Only the fraction of the medication in the 
maternal plasma that is not protein bound 
can leave the maternal circulation, diffuse 
across the alveolar membrane, and accumu-
late in the breast milk. Casein, alpha-lactal-
bumin, lactoferrin, and immunoglobulinA 
(IgA), the main milk proteins in breast milk, 
do not bind drugs well.4 More than half of 
Drugs with a molecular weight of 
more than 200 kilodaltons, such as 
heparin and insulin, are unable to 
cross the alveolar membrane. 
the plasma protein in the maternal circula-
tion is albumin, a major drug-binding pro-
tein. The high protein binding in the mater-
nal plasma effectively restricts many drugs 
to the plasma compartment and are not 
transferred into the breast milk. Thus highly 
protein-bound medications, such as pheny-
toin (Dilantin), are excreted into the breast 
milk in small amounts. 
Lipid solubility 
The more lipid soluble the drug, the 
greater the quantity and the faster the trans-
fer into breast milk. Lipid-soluble drugs 
cross cell membranes more rapidly by dis-
solving in the lipid bilayer. In contrast, a 
water-soluble drug must cross the cell mem-
branes through the pores. Thus drugs with 
a low lipid solubility diffuse slower into 
the breast milk. 5 For example, diazepam 
(Valium), which is very lipid soluble, rap-
idly accumulates in the breast milk. 6 
Drug pH ionization 
While average plasma pH is 7.4, the mean 
pH of breast milk is 7.2, which is signifi-
cantly lower. 7 Weak acids are ionized in the 
maternal plasma, decreasing their passage 
into the breast milk. Weak bases are 
nonionized in the maternal plasma, increas-
ing their lipid solubility and transfer into 
breast milk. At the lower pH of breast milk 
some weak bases will become ionized, pre-
venting diffusion back across the membrane. 
As a result, the drug molecule becomes 
trapped in the breast milk and may achieve 
a higher concentration than otherwise pre-
dicted. Conversely, drugs that are more acidic 
tend to concentrate in the maternal plasma 
and do not readily transfer into breast milk. 
For example, erythromycin and antihista-
mines, drugs that are weak bases, would be 
more likely to cross the membranes from 
plasma into breast milk than barbiturates 
and penicillins, drugs that are weak acids.8 
Half-life of the drug 
The half-life of a drug is determined by 
the drug's volume of distribution and clear-
ance. Half-life varies greatly from one drug 
to another. For example, the half-life of 
ampicillin is 1 hour, Coumadin about 36 
hours, and digoxin approximately 1 week. 9 
A drug with a short half-life will have 
plasma concentrations that fluctuate the 
most and must be taken more frequently 
than a drug with a longer half-life to main-
tain therapeutic levels. Thus the longer the 
half-life of the drug over time, the greater 
the accumulation will be in the mother, in 
the breast milk, and in the infant. 
Maternal factors 
Several maternal factors influence the 
plasma level of a drug in the breast milk. 
These factors include the dose, frequency, 
timing and route of administration, the 
mother's health, breast milk composition, 
and breast anatomy. 
Dose 
The dose of the medication is one factor 
that determines how much of the drug will 
enter the maternal circulation and the breast 
milk. The higher the dose, the more drug 
passes into breast milk. Thus the recom-
mendation to use the lowest dose needed 
decreases the amount of a drug that will 
pass into the breast milk. 
Route of administration 
The route of administration determines 
how much of the medication will enter the 
maternal circulation and, therefore, the 
breast milk. The medication may be ad-
ministered through one of several routes, 
such as intravenously, intramuscularly, 
orally, topically, or by inhalation. The 
intravenous (IV) route allows a drug to 
transfer into the breast milk without con-
sideration of an absorption factor. The 
amount of a drug that enters the plasma 
following all other routes of administra-
tion is decreased compared with IV dos-
ing. Thus breast milk levels will be highest 
following IV dosing compared with other 
routes. 
Timing of medication 
Breast milk is manufactured while the 
infant is suckling. The breast stores only a 
small amount of breast milk between 
feedings. Thus the timing of a drug dose in 
relation to breastfeeding influences how 
much of the drug will appear in the breast 
milk. For example, if the infant is 
breastfeeding when the maternal serum drug 
level is peaking, the amount of a drug that 
transfers to the breast milk is higher than if 
her serum level is at a trough. In addition, 
the blood flow to the breast increases when 
the breasts begin to lactate. A peaking drug-
serum level combined with an increase in 
mammary blood flow will deliver a higher 
amount of the drug to the milk. Conversely 
a drug taken immediate! y after breastfeeding 
has the maximum time to clear the maternal 
blood. However, with a newborn who is 
breastfeeding more than eight times a day, 
trying to time the dose is nearly impossible. 
Maternal health 
The mother's health is another factor of 
drug transfer into the breast milk. If the 
mother's ability to clear the medication is 
impaired, such as by poor liver or kidney 
function, a greater quantity can accumulate 
in the breast milk and be ingested by the 
infant. 
Composition of breast milk 
The composition of the maternal breast 
milk also affects the ability of the drug to 
cross the plasma into the milk. Colostrum 
is high in proteins and low in lactose and 
fat. As mature milk develops, this ratio is 
reversed. As the protein, fat, water, and 
sugar content changes, the drug transfer 
mechanisms change. Lipid-soluble drugs 
may concentrate in the breast milk fat. The 
usual amount of fat in breast milk is low 
when compared with the total milk vol-
ume. As a result, the amount of a drug that 
reaches the infant is probably small with 
mature milk. 
Breast anatomy 
Immediately after birth, the spaces be-
tween the myoepithelial cells ofthe alveo-
lus are large and allow the passage of 
larger plasma proteins like IgA. However, 
these spaces close to become small pores 
within a week. As a result, the passage is 
restricted to lower molecular weight, wa-
ter-soluble, nonelectrolytes. 
Blood-milk barrier 
A drug in the mother's blood stream must 
first pass out of the blood capillary into the 
connective tissue surrounding the secre-
tory lobes. To pass through the alveolar 
lumen, the drug must penetrate the mem-
branes of myoepithelial cells and walls of 
the secretory cells lining the alveolus (Fig 
5). This penetration is accomplished by 
either diffusion through the lipid portion 
of the membranes or through protein chan-
nels in the membranes. Passive diffusion of 
drugs is most common. A secondary route 
is to pass through the alveolar lumen via 
small intercellular clefts, bypassing the 
secretory and myoepithelial cells. 
Infant factors 
Infants are continually growing and ma-
turing, especially the premature infant. 
Thus what adversely affects the newborn at 
one point in time may not be an issue a 
week or a month later. There are several 
infant factors that influence the plasma 
drug level in the infant acquired from the 
breast milk. These factors include absorp-
tion, protein binding, hepatic metabolism, 
renal excretion, and frequency and volume 
of feedings. 
Absorption 
In infants, gastric emptying time is de-
layed and intestinal absorption is irregular, 
resulting in delayed absorption of some 
drugs. In addition, the infant has a higher 
gastric pH during the first few days of life, 
probably allowing gastric absorption of 
weak bases that would not occur later.10 
Other factors that can influence drug ab-
sorption are the infant's gastrointestinal 
flora and reduced amounts of bile salts and 
pancreatic enzymes. 
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Fig 5. Simplistic diagram of the blood-milk pathway. 
Protein binding 
Less protein and less binding per unit 
protein in the infant compared with the 
adult results in increased clearance ofhighly 
protein-bound drugs by glomerular filtra-
tion. This appears to compensate for the 
decrease in clearance observed due to im-
mature glomerular function. The infant 
approaches adult values for protein bind-
ing by 10 to 12 months of age.U 
Renal excretion 
Glomerular filtration and tubular secre-
tions are both underdeveloped in the neo-
nate at birth. Immediately following deliv-
ery there is a rapid maturation of the kidneys. 
By 2 to 3 days postdelivery, the glomerular 
filtration rate (GFR) values are three times 
those of the first day of deliveryY As a 
result, a term newborn will have a GFR of 
one third of adult values. In contrast, a 
preterm newborn born at 28 weeks will have 
only a GFR of 10% of adult values.13 The 
GFR approximately doubles during the first 
2 weeks after delivery, reaching adult GFR 
values between 2 to 5 months of age.14 
Tubular development lags behind glom-
erular development. Functional tubular 
maturation is not reached until7 to 9 months 
of age.15 
Metabolism 
Hepatic enzymes responsible for the 
metabolism of exogenous and endogenous 
compounds mature at varying rates. For 
example, phenytoin (Dilantin) is metabo-
lized at adult rates within 1 to 2 weeks of 
delivery. However, theophylline metabo-
lism in the infant does not reach adult 
capacity until 1 year of age.16 
Conjugation capacity of the newborn is 
poor and frequently variable. The impaired 
conjugation of bilirubin is one factor con-
tributing to high unconjugated bilirubin 
concentrations in the newborn.17 A healthy, 
term newborn will not need to have close 
monitoring of bilirubin levels if the mother 
is taking sulfamethoxazole-trimethoprim 
(Bactrim) and is breastfeeding. However, if 
the newborn is ill, stressed, premature, or 
has hyperbilirubinemia, an alternative 
medication for the mother should be rec-
ommended as it competes with bilirubin 
for albumin-binding sites. As a result, there 
is an increase in free bilirubin in the plasma. 
Other metabolic reactions are also re-
duced. For example, esterase activity is 
approximately 25% of an adult level in 
newborns born 4 to 7 weeks early. This 
increases to 33% at term, but does not 
approach adult capacity until after 1 year .16 
Frequency and volume of feedings 
The frequency of breastfeeding and vol-
ume ofbreast milk must be considered. The 
infant that is breastfeeding only once or 
twice a day and taking solids and juices 
consumes much less than the neonate who 
is breastfeeding eight times or more a day 
and not taking any solids. 
STRATEGIES TO MINIMIZE INFANT 
EXPOSURE AND RISK TO DRUGS 
~EBREASTFEEDUNG 
Often a mother will be instructed to stop 
breastfeeding when a drug is prescribed or 
recommended. This recommendation is 
usually unjustified and reflects a lack of 
knowledge regarding drugs and breast feed-
ing. The following strategies were devel-
oped from the WellStart/The San Diego Lac-
tation Program.19 The goal is to minimize 
the infant's exposure to drugs in the breast 
milk. These strategies should be used with 
available information on the specific drug or 
drugs being considered for the lactating 
mother, such as the American Academy of 
Pediatrics (AAP) Committee on Drugs state-
ment on The Transfer of Drugs and Other 
Chemicals into Human Milk. 20 
Essential medication 
Often the medication is nonessential. 
Thus the nurse should question the mother's 
need for the drug. For example, recom-
mend a single-cold product to treat only 
one or two symptoms, rather than a 
multicold product. 
Delayed therapy 
An elective surgery may be postponed un-
til after the mother has stopped breastfeeding. 
Established history 
Little or no information on a newer drug 
on the market may be available regarding 
the safety or pharmacokinetics for the breast-
feeding mother. An older drug may provide 
more reassurance as to the risks to the infant. 
Poor passage into milk 
Within a class of drugs, there may be a 
wide amount in the degree of drug that 
passes into breast milk. Reviewing the list of 
available drugs to identify one that is poorly 
transferred into breast milk and has mini-
malactivitywouldgreatlyreducetheinfant's 
exposure. If the mother needs a mild analge-
sic, the list includes acetaminophen, aspi-
rin, and ibuprofen. Of these three, acetami-
nophen and ibuprofen are preferred to 
aspirin. Acetaminophen rapidly enters the 
maternal circulation. The amount of ac-
etaminophen in the breast milk, however, is 
very small. Ibuprofen does not cross into 
breast milk. In contrast, aspirin crosses into 
breast milk and is slower to be eliminated 
from the milk than the plasma. A cumula-
tive effect from aspirin could have conse-
quences for the nursing infant. 
Alternative routes of administration 
Attempting to decrease the maternal 
blood-drug concentration will lower the 
amount of a drug in the breast milk that is 
?assed on to the infant. For example, an 
mhaled bronchodilator will minimize the 
amount of drug passed into breast milk 
compared to an oral agent for asthma. 
Milk production 
Certain drugs decrease prolactin levels 
and thereby decrease milk production (Table 
1). As a result, the mother is forced to stop 
breastfeeding earlier than planned or the 
need for supplementation with formula re-
sults or both. If the mother has resumed 
taking oral contraception, she should take 
an oral contraception that contains only 
progestin without estrogen. Estrogen de-
creases prolactin levels, thus decreasing 
breast milk volume and duration of lacta-
tion. In contrast, progestin has no effect on 
breast milk production or duration of lacta-
~on. However, most recommend that proges-
tin-only oral contraception therapy be started 
only after breastfeeding is well established, 
usually after 6 weeks. 
Peak drug concentrations 
When possible, coordinate drug-dosing 
times with nursing times to avoid 
breastfeeding when peak drug concentra-
tions are present in the maternal serum. This 
works best with drugs that have a short half-
life, such as ampicillin. Peak drug concen-
tration of oral medications occurs 1 to 3 
hours after the dose. If the mother can nurse 
just before the dose, this will reduce the 
amount that the infant will receive. This 
plan does not work for the newborn who is 
nursing frequently or is on an irregular sched-
Coordinate drug-dosing times with 
nursing times to avoid breast-
feeding when peak drug 
concentrations are present in the 
maternal serum. 
Table 1. Medications that decrease breast milk volume 
Generic name 
Alcohol (excessive) 
Androgens 
Antihistamines 
Apomorphine 
Barbiturates 
Bromocriptine 
Erocryptine 
Estrogens 
Levodopa 
Phenelzine 
Prostaglandin E2 
Pyridoxine 
Tranylcypromine 
Trade name 
(Numerous) 
(Numerous) 
Apomorphine 
(Numerous) 
Parlodel 
Ergocryptine 
(Numerous) 
Dopar, Larodopa 
Nardil 
Vitamin B6 
Parnate 
Source: Adapted from Riordan]. Drugs and breastfeeding. In: Riordan J, Auerbach KG. Breastfeeding and Human 
Lactation. Copyright© 1993 Jones and Bartlett. 
ule. In addition, encourage the mother to 
take a nonextended- rather than an extended-
release form of the medication. 
Infant sleep period 
With long-acting drugs that can be given 
once a day, maternal administration just 
before the infant's longest period of sleep 
may help to reduce the amount of drug 
transferred into the breast milk. For ex-
ample, warfarin (Coumadin) should be 
given after the last feeding of the day. 
Temporary withholding of breastfeeding 
Sometimes taking a drug that would be 
harmful to the infant is necessary for the 
mother. If known in advance to drug 
therapy, the mother may decide to pump 
extra breast milk that can be frozen for 
later use or temporarily to substitute for-
mula or both. While the mother is on this 
medication, she will need to use a piston 
electrical breast pump to maintain lacta-
tion and must then discard the expressed 
milk. If the mother is given metronidazole 
(Flagyl) to treat trichomoniasis, 
breastfeeding should be interrupted for 24 
hours and an alternative feeding method 
should be used. 21 
If the mother needs radioactive pharma-
ceutical, she must temporarily stop 
breastfeeding. The mother should be encour-
aged to inform the nuclear medicine physi-
cian before the diagnostic study that she is 
breastfeeding and of her desire that a radio-
nuclide with the shortest half-life in breast 
milk be used. The mother will need to use the 
piston electrical breast pump to maintain her 
milk supply, but should discard all her ex-
pressed milk for the required time that the 
radioactivity is present in the breast milk. 
This may vary from 1 day to 2 weeks. 22 
Discontinuation of nursing 
Usually it is not necessary to stop nursing 
completely when taking a drug. However, a 
  
Table 2. Drugs that are contraindicated during breastfeeding 
Generic name Reported sign or symptom in infant or effect on lactation 
Bromocriptine 
Cyclophosphamide 
Suppresses lactation 
Possible immune suppression. Unknown effect on growth or 
association with carcinogenesis. Neutropenia. 
Cyclosporine Possible immune suppression. Unknown effect on growth or 
association with carcinogenesis. 
Doxorubicin Possible immune suppression. Unknown effect on growth or 
association with carcinogenesis. 
Ergotamine 
Lithium 
Methotrexate 
Vomiting, diarrhea, convulsions. 
Phenindione 
1/3 to 1/2 therapeutic blood concentrations in infants. 
Possible immune suppression. Unknown effect on growth or 
association with carcinogenesis. Neutropenia. 
Anticoagulant. Increased prothrombin and partial thrombo-
plastin time in one infant (not used in United States). 
Source: Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into 
human milk. Pediatrics. 1994;93:137-150. 
few drugs require that the mother stop 
breastfeeding due to the toxicity for the 
infant. (See Table 2). 
SOURCES OF INFORMATION 
Several reviews on drug use during 
breastfeeding have been published. How-
ever, the AAP Committee on Drugs has a 
statement that is of particular importance. 23 
This statement is invaluable, as the AAP is 
considered an authority on the transfer of 
drugs into breast milk. A health care pro-
vider may be persuaded to continue to 
allow a mother to breastfeed when the 
drug is listed as safe by the AAP. However, 
the list is not without problems. The list 
lacks differentiation of whether the new-
born is premature, full term, or an infant; 
data on the effect of the drug on lactation; 
and data on comparisons within drug 
classes. 
Drugs in Pregnancy and Lactation is a 
detailed reference book that compiles the 
research literature and the AAP recom-
mendations.24 This book is available for 
less than $100. The most detailed source is 
Drugs and Human Lactation, compiled by 
the World Health Organization. 25 The sum-
marized qualitative and quantitative as-
pects are based upon scientific published 
data. Unfortunately the cost may be pro-
hibitive at more than $250. 
Many communities have drug informa-
tion centers with hotlines that dissemi-
nate information on issues related to drug 
therapy. The goal of the drug information 
centers is to present accurate and unbi-
ased information on patient-related prob-
lems with drug therapy. There are three 
different types of drug information cen-
ters: university affiliated, usually with a 
college of pharmacy; hospital affiliated, 
usually with a department of pharmacy; 
and pharmaceutical-industry affiliated. 
For inquiries specific to drug use in lacta-
tion, the drug, dose, and duration of therapy 
for the mother are needed. In addition, 
specific information regarding the infant 
is needed, such as the age and well-being 
of the infant. The caller should have as 
much information as possible when call-
ing the drug information center. Many 
drug information requests require time to 
investigate. 
Some drug information centers restrict 
their services to health care professionals, 
a specific health care facility, or even a 
geographic area. Thus not all drug informa-
tion centers are able or have the capacity to 
handle requests from outside their institu-
tions. One should identify the closest drug 
information center available that will pro-
vide the needed service. A comprehensive 
list of drug information centers is available 
in an annual pharmacists' reference known 
as the Drug Topics Red Book. 26 
A "fax-on-demand" service for informa-
tion on drugs in breast milk is available for 
a fee. Lactation Fax Hotline is a service that 
originated from a computerized database 
on information on drugs in breast milk. 27 
After punching the drug selection number(s) 
from Medications in Mother's Milk into a 
push button telephone, the documents are 
received within minutes from the fax ma-
chine 24 hours a day, 7 days a week. The 
business number for the service is 1-800-
378-1317. 
The drug profile includes the generic 
and brand name(s), pharmacologic cat-
egory, AAP compatibility assessment, a 
summary of the drug's normal 
indication(s), propensity to distribute in 
breast milk, references, and pharmacoki-
netic parameters. This information is usu-
ally summarized as a one-page document. 
The documents can be faxed directly to 
the subscriber of the serv-ice or to some-
one else, such as a lactation consultant or 
pharmacist, anywhere in the world as long 
as the subscriber is within the United 
  
States. This easy-to-use service is 
affordably priced: $10 registration fee for 
the first 10 faxes, then $1 per selection. 
There are, however, a few shortcomings 
to the service. At the bottom of each page, 
six pharmacokinetic parameters (adult 
half-life, pediatric half-life, oral 
bioavailability, time-to-peak, milk: plasma 
ratio, and protein binding) are listed. These 
are useful if one is familiar with the terms. 
However, no explanation comes with the 
terms to assist in determining what each 
term means or how it plays a significant 
role in the breast-fed infant. On some medi-
cations, the pharmacokinetic parameter 
section is empty. One must assume that 
there are no data available. In addition, 
one must have the book, Medications in 
Mother's Milk, to identify what drug infor-
mation is desired. 
• • • 
Breastfeeding has many well-established 
benefits for the mother and infant. Nurs-
ing mothers frequently ask questions re-
garding the safety of a medication. Basi-
cally most drugs do pass into breast milk, 
most appearing only in small amounts. 
Very few drugs, however, are truly con-
traindicated for the nursing mother. The 
mother's need for a medication is not a 
reason to stop breastfeeding. There are 
many ways to obtain information on drug 
use during lactation. After obtaining in-
formation on the specific drug(s), the 
mother should be assisted to use strategies 
to minimize her infant's exposure and risk 
to the medication while breastfeeding. By 
understanding the principles of drug pas-
sage into breast milk and evaluating the 
mother's needs, a plan can usually be 
developed that allows the benefits of 
breastfeeding. 
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